Posted by Michael Wonder on 09 May 2017
FDA grants fast track designation to XyloCor Therapeutics lead candidate XC001
8 May 2017 - XyloCor Therapeutics announced that the U.S. FDA has granted fast track designation to its lead product candidate XC001 (AdVEGF-All6A+), a cardiovascular angiogenic gene therapy.
XC001 is a one-time treatment being investigated for improving exercise tolerance in patients who have chronic angina that is refractory to standard medical therapy and not amenable to conventional revascularisation procedures such as coronary artery bypass surgery and percutaneous coronary intervention and stents.
